Annika Auranen - Gynecology

Author Information

Annika Auranen is affiliated with the Department of Obstetrics and Gynecology and the Tays Cancer Centre at Tampere University Hospital in Finland. Her work is primarily focused on gynecological oncology, with a specific interest in ovarian cancer, cancer screening, and surgical outcomes in gynecologic malignancies.

Research Contributions

Annika Auranen has made significant contributions to the field of gynecology, particularly in the management and treatment of ovarian cancer. Recent notable works include studies on ultra-radical surgery in advanced epithelial ovarian cancer, quality-adjusted time without symptom or toxicity in maintenance niraparib for advanced ovarian cancer, and the impact of surgical paradigm changes on overall survival in ovarian cancer patients. Additionally, she has contributed to guidelines for managing Peutz–Jeghers Syndrome and has explored the implications of polygenic and clinical risk scores in predicting cardiometabolic diseases and common cancers. Her research has been published in reputable journals such as Gynecologic Oncology, Annals of Oncology, and International Journal of Gynecologic Cancer.

Aliases

Annika Auranen is also known by several aliases including A A Auranen, A Auranen, and A. Auranen.

Publication and Citation Metrics

Metric	Value
Citation Count	2666
H-Index	26
Paper Count	95

Publications:

Improved survival after implementation of ultra-radical surgery in advanced epithelial ovarian cancer: Results from a tertiary referral center.

DOI: 10.1016/j.ygyno.2022.03.023

Year: 2022

738P Quality-adjusted time without symptom or toxicity (QA-TWiST) and quality-adjusted progression-free survival (QA-PFS) of first-line (1L) maintenance niraparib in patients with advanced ovarian cancer (OC): Results from the PRIMA trial

DOI: 10.1016/j.annonc.2021.08.1180

Year: 2021

Quality-adjusted time without symptom or toxicity and quality-adjusted progression-free survival of first-line maintenance niraparib in patients with advanced ovarian cancer

DOI: 10.3802/jgo.2021.32.s1.oo8

Year: 2021

1195 Results of NSGO-OV-UMB1/ENGOT-OV30 study: a phase II study of durvalumab and oleclumab in patients with relapsed ovarian cancer (OC)

DOI: 10.1136/ijgc-2021-esgo.668

Year: 2021

The Management of Peutz–Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline †

DOI: 10.3390/jcm10030473

Year: 2021

Decreasing trend and changing indications of hysterectomy in Finland

DOI: 10.1111/aogs.14159

Year: 2021

121 Effect of surgical paradigm change on overall survival in patients with advanced epithelial ovarian cancer

DOI: 10.1136/ijgc-2021-esgo.340

Year: 2021

Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers

DOI: 10.1038/s41591-020-0800-0

Year: 2020

Cancer screening – Why do we still debate about the benefits?

DOI: 10.1111/aogs.13829

Year: 2020

Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report

DOI: 10.1038/s41436-020-01029-1

Year: 2020

When is White Discharge Normal?

What is the American Academy of Professional Coders (AAPC)?

What Are the Challenges Related to PTO in Gynecology?

How Does CYP2C19 Affect Hormone Therapy?

What are the Types of IUGR?

Why is Bonding Important in Gynecology?

What Are the Advantages of Online Courses?

How Can Gynecology Practices Track Denials Effectively?

What are Checkpoint Inhibitors?

When is Operative Hysteroscopy Indicated?

Partnered Content Networks

Relevant Topics